◊ IL-4/IL-13 dual antagonist in oxazolone colitis model (67, 68) - Reduced overall disease activity◊ IL-4/IL-13 blocking trough a shared receptor (69, 71)- Reduced overall disease severity. Here, IL4 is linked to colitis.